(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.3%.
Vaxcyte's earnings in 2026 is -$766,628,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$1,049,064,295, with the lowest PCVX earnings forecast at -$1,239,758,774, and the highest PCVX earnings forecast at -$891,586,636. On average, 11 Wall Street analysts forecast PCVX's earnings for 2027 to be -$975,794,440, with the lowest PCVX earnings forecast at -$1,211,550,383, and the highest PCVX earnings forecast at -$781,271,680.
In 2028, PCVX is forecast to generate -$812,675,102 in earnings, with the lowest earnings forecast at -$992,935,355 and the highest earnings forecast at -$710,246,982.